Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904202 · ClinicalTrials.gov registry record · Phase 4
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
A Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT00904202 is a Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 62 participants, below the 78-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (21% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00904202, a Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety of Lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients.
Conditions Studied
Interventions
- DRUG Placebo Capsules + Placebo Patch
- DRUG Placebo capsules + Lidoderm®
- DRUG Gabapentin + Placebo
- DRUG Gabapentin + Lidoderm®
- DRUG Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Study Locations (7)
Alabama
- - Birmingham
- - Hueytown
New York
- - New York
- - Rochester
Arizona
- - Phoenix
Florida
- - Pembroke Pines
Pennsylvania
- - Altoona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2003-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904202
The ClinicalTrials.gov registry entry for NCT00904202 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (21% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Peripheral Neuropathy appearing as the primary indexed condition, and to 5 interventions - of which Placebo Capsules + Placebo Patch is the first listed.
NCT00904202 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Alabama, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT00904202 about?
NCT00904202 is a clinical study titled "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions". Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety o...
What is the current status of trial NCT00904202?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2003-01.
What conditions does trial NCT00904202 study?
This clinical trial studies the following conditions: Peripheral Neuropathy, Carpal Tunnel Syndrome, Diabetic Neuropathy, Complex Regional Pain Syndrome, HIV Neuropathy.
What interventions are being tested in trial NCT00904202?
The interventions under investigation include: Placebo Capsules + Placebo Patch (DRUG), Placebo capsules + Lidoderm® (DRUG), Gabapentin + Placebo (DRUG), Gabapentin + Lidoderm® (DRUG), Gabapentin 300 mg capsules 1800 mg/day + placebo patch (DRUG).
Who is sponsoring clinical trial NCT00904202?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904202 being conducted?
This trial has 7 study locations across Alabama, Arizona, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
RECRUITING
-
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
RECRUITING
-
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
DoD AtMS for Posttraumatic Peripheral Neuropathic Pain
RECRUITING · NA
-
Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.